Triple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz238.010
Abstract: Abstract Background Molecular mechanisms driving acquired resistance to anti-EGFR therapies in metastatic Colorectal Cancer (mCRC) are complex but generally involve the activation of the downstream RAS-RAF-MEK-MAPK pathway. Methods In order to understand the mechanism underlying… read more here.
Keywords: meki; egfr; mek inhibitor; treatment ... See more keywords
MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Research"
DOI: 10.1158/0008-5472.can-20-2370
Abstract: This study provides key insights into the potential for using MEKi combined with PARPi and anti-PD-L1 for the treatment of all mutant KRAS tumors. Mutant KRAS tumors are associated with poor outcomes, at least in… read more here.
Keywords: parp; immune checkpoint; resistance; meki ... See more keywords
Abstract A121: Adaptive and acquired signaling response to MEK inhibition in NF1-associated malignant peripheral nerve sheath tumor
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-a121
Abstract: Background: About 50% of MPNST arise in patients with neurofibromatosis type 1, and these tumors are among the most difficult types of soft tissue sarcoma to manage. NF1 is a tumor suppressor gene essential for… read more here.
Keywords: resistance; tumor; mek inhibition; meki ... See more keywords
Abstract 2711: Smart encapsulation of a MEK inhibitor into M2-9SLP/mApoE-liposomes for specific GBM targeting
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2711
Abstract: Among the main aberrations occurring in GBM, those in MEK/ERK and PI3K/akt/mTOR pathways predominate and confer GBM Stem-like Cells (GSCs) sustained proliferation and resistance to therapy. A panel of eight patient-derived primary GSCs lines have… read more here.
Keywords: 9slp mapoe; cell; inhibitor; mek ... See more keywords
Abstract 3876: Kinetics of RTK activation determine ERK signaling dynamics and resistance to BRAF and MEK inhibitors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3876
Abstract: Combination treatment of BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) produces remarkable response rates and is expected to prevent ERK activation in BRAF-mutant melanoma. However, sporadic ERK reactivation occurs in melanoma models, and efficacy is… read more here.
Keywords: braf; resistance; erk; rtk activation ... See more keywords
Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-19-0672
Abstract: Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K mutant melanoma. Efficacy of BRAFi + MEKi associates with cancer cell death and alterations in the tumor immune microenvironment;… read more here.
Keywords: brafi meki; pyroptosis; meki; tumor immune ... See more keywords
A new B-Raf inhibitor combo for advanced melanoma
Sign Up to like & getrecommendations! Published in 2018 at "Oncotarget"
DOI: 10.18632/oncotarget.26171
Abstract: During the last decade, several new treatment modalities have been developed, that impressively improved survival and quality of life in patients with advanced melanoma, who did not face any progress since more than 50 years… read more here.
Keywords: meki; combination; advanced melanoma; inhibitor ... See more keywords
Antigen Peptide Transporter 1 (TAP1) Promotes Resistance to MEK Inhibitors in Pancreatic Cancers
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23137168
Abstract: Mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitors show limited benefit in Kirsten rat sarcoma (KRAS) mutant pancreatic cancer due to drug resistance. To identify mechanisms of resistance to MEK inhibitor (MEKi), we employed a differential… read more here.
Keywords: meki resistant; mek inhibitors; resistance; resistance mek ... See more keywords